Skip to main content

Table 2 Correlation between PGI-S and other baseline BPH Measures in all patients

From: Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

PGI-S (baseline visit) n (%) Mean IPSS (SD) Mean IPSS-QoL (SD) Mean BII (SD) Mean Qmax (SD)
Normal 18 (1.1%) 14.9 (2.9) 2.4 (0.6) 1.1 (1.4) 10.4 (2.4)
Mild 376 (22.2%) 16.8 (3.9) 3.5 (1.1) 4.0 (2.4) 10.4 (2.7)
Moderate 1039 (61.4%) 19.8 (4.7) 4.1 (1.0) 6.7 (2.5) 9.9 (2.8)
Severe 259 (15.3%) 24.2 (5.5) 5.0 (0.9) 9.1 (2.6) 9.6 (2.9)
Overall comparison p-value   <0.001 <0.001 <0.001 0.003
Pairwise comparison p-value      
  Normal vs. Mild   0.092 <0.001 <0.001 0.993
  Normal vs. Moderate   <0.001 <0.001 <0.001 0.461
  Normal vs. Severe   <0.001 <0.001 <0.001 0.273
  Mild vs. Moderate   <0.001 <0.001 <0.001 0.002
  Mild vs. Severe   <0.001 <0.001 <0.001 <0.001
  Moderate vs. Severe   <0.001 <0.001 <0.001 0.171
Spearman’s Correlation   0.43** 0.43** 0.53** −0.09**
  1. PGI-S: Patient Global Impression of Severity; IPSS: International Prostate Symptom Scores; IPSS QoL: IPSS-Quality of Life (QoL), BII - Benign Prostatic Hyperplasia Impact Index; Qmax: peak urine flow rate; n: number of patients; SD: Standard Deviation. Overall and pairwise comparison p-values are from analysis of variance without adjusting for covariates. **: p<0.001.